Search
On May 19, Full-Life Technologies made an announcement regarding the successful completion of a funding round that surpassed RMB 1 billion. This funding encompasses roughly RMB 750 million in Series D equity financing and an additional RMB 270 million in debt financing. The capital raised will be strategically allocated to propel the development of clinical-stage pipelines and to facilitate the construction of production facilities in Belgium.
On the very same day, JINGHUO Biopharmaceuticals, an innovative nuclear medicine company, also declared the successful closure of its Series B financing round, amassing nearly RMB 400 million. These funds are earmarked for conducting clinical research on its core pipelines, upgrading its technology platforms, and establishing a research and development center dedicated to radioactive drugs.
-
C114 Communication Network -
Communication Home
